Tamoral - Tablet Tamoxifen - 10mg 1 Tablet(s) / Tablet Techno Drugs LTD. Introduction: Tamoral is an anti-estrogens. It is used in the treatment of breast cancer. It is also used to reduce the risk of breast cancer in women with a high chance of developing it. This medicine helps to slow down the growth and multiplication of cancer cells. Tamoral is also helpful in the treatment of infertility. It can be taken with or without food, but take it at the same time to get the most benefit. It should be taken as your doctor's advice. The dose and how often you take it depends on what you are taking it for. Your... Uses of Tamoral: Breast cancer Side effects of Tamoral: NauseaSkin rashHot flashesThinning of hairVaginal dischargeSwelling How to use Tamoral: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tamoral may be taken with or without food, but it is better to take it at a fixed time. How Tamoral works: Tamoral is a hormone-based medication. It works by binding to estrogen receptors and blocking the effects of estrogen (a natural female hormone) in the breast tissue. This slows down the growth and multiplication of breast cancer cells. Indication: Breast cancer Administration: May be taken with or without food. Adult Dose: Oral Breast Cancer Treatment 20 mg daily as a single or in 2 divided doses. Max: 40 mg daily. Continue with adjuvant therapy for at least 5 years For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10 Breast Cancer Prevention Indicated to reduce the incidence of breast cancer in women at high risk for breast cancer; high risk is defined as women aged >35 years with a 5-year predicted risk of breast cancer >1.67% (calculated by the Gail Model) Adult: 20... Contraindication: History of DVT or pulmonary embolism. Pregnancy and lactation. Concomitant coumarin-type anticoagulant therapy. Mode of Action: Tamoxifen, a triphenylethylene derivative, produces a nuclear complex by competitively binding to oestrogen receptors on tumours and other tissue targets thus, decreasing DNA synthesis and inhibiting oestrogen effect. It is only cytostatic rather than cytotoxic due to accumulation of cell in G0 and G1 phases. Precaution: Patient w/ leucopenia and thrombocytopenia, hyperlipidaemias. Monitoring Parameters Perform periodic CBC (e.g. platelet counts) and LFTs. Routine gynaecological monitoring and any abnormal symptoms (e.g. abnormal vag bleeding or discharge, pelvic pain, menstrual irregularities). Lactation: not known if excreted in breast milk, do not nurse Side Effect: >10% Hot flashes (64%),Vaginal discharge (30%),Amenorrhea (16%),Menstrual changes (13%) 1-10% Oligomenorrhea (9%),Cataracts (8%),Bone pain (6%),Nausea (5%),Cough (4%),Edema (4%),Fatigue (4%),Musculoskeletal pain (3%),Ovarian cyst (3%),Depression (2%),Abdominal cramps (1%),Anorexia (1%) <1% Angioedema,Corneal changes,Loss of libido,Endometrial cancer,Pancreatitis,Retinal vein thrombosis,Stroke,Uterine fibroids Potentially Fatal: Blood dyscrasias, cholestasis, hepatitis, hypercalcaemia in patients with bone metastasis, thromboembolic events. Increased risk of endometrial cancer and uterine sarcoma. Interaction: Increases dopaminergic effect of bromocriptine. Increased risk of thromboembolic events w/ cytotoxic drugs. Increased risk of bleeding w/ platelet aggregation inhibitors. May mutually reduce effects w/ hormone preparations particularly oestrogens (e.g. OCs). Reduced plasma levels w/ CYP3A4 inducers (e.g rifampicin) and CYP2D6 inhibitors. Increased plasma levels w/ CYP3A4 inhibitors. Potentially Fatal: Significant increase in anticoagulant effect w/ coumarin-type anticoagulants (e.g. warfarin).